Effect of procetofen on apolipoprotein A I and B concentrations in hyperlipoproteinemia.
Thirty-three hyperlipoproteinemic patients were subjected to therapy with procetofen (300-600 mg daily) for 6 months in a placebo-controlled study. Lipoprotein changes based on cholesterol fractions have been reported previously. This report shows that procetofen increase Apo A I only slightly. Apoprotein B decreased by 16% and the ratio of Apo A I to Apo B was increased by 31%. In addition, procetofen induces changes in HDL composition: the relative amount of cholesterol is increased, which may reflect more efficient efflux of cholesterol from the tissues.
D000328:Adult; D016632:Apolipoprotein A-I; D001053:Apolipoproteins / Q000097:blood*; D001055:Apolipoproteins B; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D011345:Fenofibrate / Q000494:pharmacology*; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood* / Q000188:drug therapy; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008875:Middle Aged; D011422:Propionates / Q000494:pharmacology*; D013997:Time Factors
D016632:Apolipoprotein A-I; D001053:Apolipoproteins; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D011422:Propionates; D002784:Cholesterol; D011345:Fenofibrate